CYTOKINETICS, INCORPORATED (CYTK) Spending and interest coverage
- R&D / revenue · 12 months: Value 592.52%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 188.13%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 592.52% | Research and development expense / revenue. Period ending 2026-06-30. $400.96M ÷ $67.67M × 100 ≈ 592.52% |
| Stock-based compensation / revenue · 12 months | 188.13% | Share-based compensation / revenue. Period ending 2026-06-30. $127.31M ÷ $67.67M × 100 ≈ 188.13% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 400.96M USD | Research and Development Expense |
| Revenue | 67.67M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 127.31M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -707.91M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $400.96M | $67.67M | $127.31M | $-707.91M | (m) | 592.52% | 188.13% | (m) | (m) |
| 2026-03-31 | $413.29M | $105.81M | $119.13M | $-640.25M | (m) | 390.58% | 112.58% | (m) | (m) |
| 2025-12-31 | $416.03M | $88.04M | $112.29M | $-612.26M | $45.58M | 472.55% | 127.54% | -13.43× | Reported |
| 2025-09-30 | $405.26M | $87.21M | $108.03M | $-572.93M | $40.24M | 464.69% | 123.87% | -14.24× | Reported |
| 2025-06-30 | $390.64M | $85.74M | $102.69M | $-546.98M | $37.82M | 455.62% | 119.77% | -14.46× | Reported |
| 2025-03-31 | $357.68M | $19.22M | $99.78M | $-565.64M | (m) | 1861.17% | 519.19% | (m) | (m) |
| 2024-12-31 | $339.41M | $18.47M | $97.84M | $-536.25M | $37.70M | 1837.22% | 529.61% | -14.22× | Reported |
| 2024-09-30 | $330.75M | $3.22M | $91.08M | $-524.63M | $35.93M | 10275.09% | 2829.36% | -14.60× | Reported |
| 2024-06-30 | $328.68M | $3.13M | $84.44M | $-506.09M | $34.13M | 10487.40% | 2694.22% | -14.83× | Reported |
| 2024-03-31 | $332.27M | $3.75M | $78.48M | $-497.97M | $28.45M | 8855.86% | 2091.76% | -17.50× | Reported |
| 2023-12-31 | $330.12M | $7.53M | $72.06M | $-496.20M | $28.31M | 4384.10% | 957.04% | -17.53× | Reported |
| 2023-09-30 | $320.17M | $7.82M | $66.08M | $-495.82M | $28.20M | 4096.80% | 845.50% | -17.58× | Reported |
| 2023-06-30 | $300.37M | $9.95M | $60.53M | $-481.99M | $27.87M | 3018.16% | 608.27% | -17.30× | Reported |
| 2023-03-31 | $274.30M | $98.05M | $54.06M | $-370.82M | $23.63M | 279.75% | 55.14% | -15.69× | Reported |
| 2022-12-31 | $240.81M | $94.59M | $47.85M | $-324.20M | $19.41M | 254.59% | 50.59% | -16.70× | Reported |
| 2022-09-30 | $209.29M | $148.23M | $41.07M | $-218.88M | $16.57M | 141.19% | 27.70% | -13.21× | Reported |
| 2022-06-30 | $195.00M | $151.15M | $35.66M | $-179.64M | $13.93M | 129.01% | 23.59% | -12.89× | Reported |
| 2022-03-31 | $174.31M | $65.03M | $30.56M | $-223.56M | $15.20M | 268.06% | 46.99% | -14.71× | Reported |
| 2021-12-31 | $159.94M | $70.43M | $26.83M | $-186.31M | $16.44M | 227.09% | 38.10% | -11.33× | Reported |
| 2021-09-30 | $145.66M | $21.55M | $25.00M | $-201.02M | $16.24M | 675.92% | 116.00% | -12.38× | Reported |
| 2021-06-30 | $121.43M | $57.80M | $21.92M | $-126.63M | $16.05M | 210.08% | 37.93% | -7.89× | Reported |
| 2021-03-31 | $106.77M | $58.55M | $19.36M | $-104.19M | $15.87M | 182.36% | 33.06% | -6.56× | Reported |
| 2020-12-31 | $96.95M | $55.83M | $17.62M | $-93.94M | $15.96M | 173.66% | 31.56% | -5.89× | Reported |
| 2020-09-30 | $86.06M | $54.32M | $15.62M | $-81.24M | $14.68M | 158.44% | 28.75% | -5.54× | Reported |
| 2020-06-30 | $82.09M | $18.68M | $13.71M | $-110.35M | $12.04M | 439.34% | 73.37% | -9.16× | Reported |
| 2020-03-31 | $84.32M | $22.23M | $12.00M | $-104.71M | $9.53M | 379.32% | 53.99% | -10.99× | Reported |
| 2019-12-31 | $86.13M | $26.87M | $10.76M | $-98.87M | $6.62M | 320.55% | 40.04% | -14.93× | Reported |
| 2019-09-30 | $91.07M | $31.03M | (m) | $-96.62M | $5.06M | 293.46% | (m) | -19.09× | Reported |
| 2019-06-30 | $92.98M | $35.62M | (m) | $-90.61M | $4.58M | 261.04% | (m) | -19.77× | Reported |
| 2019-03-31 | $90.55M | $34.70M | (m) | $-87.30M | $4.10M | 260.96% | (m) | -21.27× | Reported |
| 2018-12-31 | $89.14M | $31.50M | $9.76M | $-88.92M | $3.80M | 282.96% | 30.99% | -23.42× | Reported |
| 2018-09-30 | $92.11M | $22.11M | (m) | $-103.98M | $3.30M | 416.67% | (m) | -31.53× | Reported |
| 2018-06-30 | $94.92M | $17.64M | (m) | $-114.50M | $3.24M | 537.91% | (m) | -35.37× | Reported |
| 2018-03-31 | $93.14M | $14.48M | (m) | $-116.28M | $3.13M | 643.11% | (m) | -37.10× | Reported |
| 2017-12-31 | $90.30M | $13.37M | $9.03M | $-113.40M | $3.02M | 675.46% | 67.53% | -37.60× | Reported |
| 2017-09-30 | $82.82M | $46.52M | $8.47M | $-69.18M | $3.06M | 178.02% | 18.20% | -22.62× | Reported |
| 2017-06-30 | $75.74M | $99.39M | $7.89M | $-6.79M | $2.97M | 76.20% | 7.94% | -2.29× | Reported |
| 2017-03-31 | $65.65M | $102.14M | $7.46M | $7.39M | $5.19M | 64.28% | 7.30% | 1.42× | Reported |
| 2016-12-31 | $59.90M | $106.41M | $7.15M | $18.69M | $2.70M | 56.29% | 6.72% | 6.93× | Reported |
| 2016-09-30 | $55.84M | $83.03M | $6.61M | $503.00K | (m) | 67.26% | 7.97% | (m) | (m) |
| 2016-06-30 | $48.06M | $31.92M | $5.87M | $-40.87M | (m) | 150.55% | 18.38% | (m) | (m) |
| 2016-03-31 | $50.98M | $32.66M | $5.28M | $-40.45M | (m) | 156.06% | 16.17% | (m) | (m) |
| 2015-12-31 | $46.40M | $28.66M | $4.57M | $-37.41M | (m) | 161.90% | 15.94% | (m) | (m) |
| 2015-09-30 | $41.93M | $40.66M | $4.11M | $-19.96M | (m) | 103.12% | 10.10% | (m) | (m) |
| 2015-06-30 | $41.79M | $42.13M | $3.88M | $-17.07M | (m) | 99.20% | 9.20% | (m) | (m) |
| 2015-03-31 | $40.89M | $43.38M | $3.53M | $-14.89M | (m) | 94.28% | 8.14% | (m) | (m) |
| 2014-12-31 | $44.43M | $46.94M | $3.33M | $-14.75M | $0.00 | 94.64% | 7.09% | (m) | Reported |
| 2014-09-30 | $49.47M | $49.53M | $3.10M | $-16.74M | (m) | 99.88% | 6.26% | (m) | (m) |
| 2014-06-30 | $51.50M | $44.59M | $3.05M | $-23.36M | (m) | 115.50% | 6.85% | (m) | (m) |
| 2014-03-31 | $52.11M | $37.81M | $3.33M | $-30.02M | (m) | 137.82% | 8.79% | (m) | (m) |
| 2013-12-31 | $49.45M | $30.65M | $3.60M | $-33.89M | (m) | 161.35% | 11.74% | (m) | (m) |
| 2013-09-30 | $45.48M | $8.48M | $3.85M | $-51.81M | (m) | 536.18% | 45.36% | (m) | (m) |
| 2013-06-30 | $40.84M | $5.73M | $4.07M | $-49.28M | (m) | 712.94% | 71.00% | (m) | (m) |
| 2013-03-31 | $36.73M | $6.56M | $3.81M | $-43.16M | (m) | 559.94% | 58.02% | (m) | (m) |
| 2012-12-31 | $35.64M | $7.56M | $3.78M | $-40.46M | $3.00K | 471.53% | 50.05% | -13485.67× | Reported |
| 2012-09-30 | $34.38M | $6.13M | $3.72M | $-40.87M | (m) | 560.73% | 60.62% | (m) | (m) |
| 2012-06-30 | $34.48M | $5.84M | $3.39M | $-41.46M | (m) | 589.96% | 57.99% | (m) | (m) |
| 2012-03-31 | $36.75M | $5.06M | $3.25M | $-46.15M | (m) | 726.68% | 64.29% | (m) | (m) |
| 2011-12-31 | $37.18M | $4.00M | $3.07M | $-47.96M | (m) | 929.55% | 76.72% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $38.01M | $2.58M | $4.02M | $-49.63M | (m) | 1475.09% | 155.88% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $39.84M | $81.54M | $4.91M | $26.09M | (m) | 48.86% | 6.02% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |